Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 2/20 | 0.57 |
| ▸ | EDNRA | P25101 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7575122 | 0.92 | EDNRB (0.60) | EDNRBEDNRAALDH1A1HTTKMT2A | |
| SCHEMBL7567566 | 0.92 | EDNRA (0.54) | EDNRBEDNRAALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL7567913 | 0.92 | EDNRA (0.54) | EDNRBEDNRAALDH1A1HTTKMT2A | |
| SCHEMBL7573901 | 0.90 | EDNRB (0.56) | EDNRBEDNRAALDH1A1HTTKMT2A | |
| SCHEMBL7567416 | 0.90 | EDNRB (0.70) | EDNRBEDNRAALDH1A1HTTKMT2A | |
| SCHEMBL7568008 | 0.90 | EDNRA (0.67) | EDNRBEDNRAALDH1A1GAA | |
| SCHEMBL7569450 | 0.87 | EDNRB (0.53) | EDNRBEDNRAALDH1A1HTTKMT2A | |
| SCHEMBL7570509 | 0.87 | EDNRA (0.49) | EDNRBEDNRAALDH1A1KMT2AGAA | |
| SCHEMBL7566448 | 0.87 | EDNRA (0.63) | EDNRBEDNRA | |
| SCHEMBL7568031 | 0.86 | EDNRB (0.65) | EDNRBEDNRAALDH1A1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0799206-B1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | claimed |
| US-5962682-A | Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists | HOFFMANN-LA ROCHE INC. (US) | 1999-10-05 | — | — | US | claimed |
| JP-2930731-B2 | — | — | 1999-08-03 | — | — | JP | claimed |
| EP-0799206-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | claimed |
| WO-1996019455-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | claimed |
| EP-0799206-B1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| US-6133442-A | FOR THE TREATMENT OF DISORDERS WHICH ARE ASSOCIATED WITH ENDOTHELIN ACTIVITIES, ESPECIALLY CIRCULATORY DISORDERS SUCH AS HYPERTENSION, ISCHAEMIA, VASOSPASMS AND ANGINA PECTORIS | HOFFMANN-LA ROCHE INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-5962682-A | Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists | HOFFMANN-LA ROCHE INC. (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0799206-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019455-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | disclosed |